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1. Introduction 
Cystic Fibrosis (CF) lung disease is characterised by progressive chronic infection and 
inflammation of the airways. This prolonged airway inflammatory response leads to 
irreversible lung damage and fibrosis which is believed to be driven by two distinct, 
coordinated events: a) a defective cystic fibrosis transmembrane regulator (CFTR) causes 
airway surface dehydration and increased mucus viscosity leading to chronic colonization 
with Pseudomonas aeruginosa (P.aeruginosa) (Boucher, 2007); b) mutated CFTR triggers the 
generation of pro-inflammatory and chemotactic cytokines orchestrated by bronchial 
epithelial cells, independently of infection (Rubin, 2007; Elizur et al., 2008). The chemokine 
IL-8, abundantly expressed at sites of chronic inflammation, seems to play a major role in 
driving the formation of neutrophil (PMN)-rich exudates into the lung of CF patients (Khan 
et al., 1995; Noah et al., 1997; DiMango et al., 1998; Puchelle et al., 2001; Joseph et al., 2005; 
Perez et al., 2007). Therefore, reduction of the exaggerated production of IL-8 is key 
therapeutic target in CF. Anti-inflammatory drugs are an attractive therapeutic tool in CF 
aimed to decrease the rate of decline in lung function. However, the inherent complexity of 
the inflammatory response combined with the obvious dependency on this response to 
contain infection and the side effect profiles of common anti-inflammatories, have made 
identifying the most suitable therapy a major priority. 
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Consensus is growing on sphingolipids (SLs) as novel targets to cure pulmonary disorders 
including CF, since modulation of cellular ceramide reduces lung inflammation (Lahiri and 
Futerman, 2007; Uhlig and Gulbins, 2008). The results in the area of ceramide and CF 
pathophysiology are very interesting, although contradicting due to the animal models used 
and methods of ceramide detection (Wojewodka , 2011). The accumulation of ceramide has 
been identified as one of the key regulators of inflammation in CF airways in different 
CFTR-/- mouse models (Teichgraber, 2008). On the contrary, decreased ceramide levels 
have been shown in CFTR ko mice (Guibault, 2008). The possible explanation for this 
discrepancy seems to be the special diet required for CFTR ko mice, that severely affects the 
concentration of SLs. Other possible causes, such as genetic determinants, could influence 
individual levels of SLs (Hicks, 2009). In a different study, no significant difference has been 
found in basal ceramide levels in immortalised CF bronchial epithelial cells and lung 
homogenate from CFTR ko mice compared to wild type cells and mice (Yu, 2009). Very 
importantly, ceramide has been demonstrated to accumulate in the lower airways of CF 
patients and to be positively associated with neutrophilic inflammation (Brodlie, 2010), 
supporting the hypothesis that reduction of ceramide may be a therapeutic target for CF 
lung inflammation.  
Extending our previous study (Dechecchi, 2008), we have recently demonstrated that the 
iminosugar N-butyldeoxynojirimycin (miglustat), an inhibitor of the first step in 
glycosphingolipid (GSL) biosynthesis, reducing the P.aeruginosa induced immunoreactive 
ceramide expression, produces an anti-inflammatory effect in human bronchial epithelial cells 
in vitro and down-regulates the neutrophil chemotaxis in murine lungs in vivo (Dechecchi, 
2011). These findings strengthen the notion that the metabolism of SLs can be manipulated as a 
therapeutic option for CF lung disease. With regard to new treatments for CF lung pathology, 
miglustat deserves great attention since it restores CFTR function in respiratory and pancreatic 
cells in vitro (Norez, 2006; Dechecchi, 2008) and in CF mice (Lubamba, 2009) and produces an 
anti-inflammatory effect in vitro and in vivo (Dechecchi, 2011). Notably, miglustat is a FDA-
approved and EMA−designated orally bioavailable orphan drug, used in Europe and USA for 
the treatment of Gaucher disease and other GSL storage diseases.  
In this chapter we review the pre-clinical evidence on the anti-inflammatory effect of 
miglustat in comparative effectiveness studies with the SL inhibitor amitriptyline and the 
glucocorticoid (GC) dexamethasone. Importance will be placed on the efficacy of each anti-
inflammatory molecule to balance between the anti-inflammatory activity and possible 
impairment of the host defence.  
2. CF bronchial cells seem to be resistant to the treatment with 
glucocorticoids 
Chronic inflammation is commonly treated by a number of approaches including fast-acting 
symptomatic drugs, such as non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids 
and slow-acting disease-modifying anti-rheumatic drugs, such as low-dose methotrexate. In 
the treatment of chronic lung inflammation of CF patients, corticosteroids and NSAIDs have 
garnered the most attention, to date. Although traditional treatments with corticosteroids and 
ibuprofen have demonstrated potential benefits in CF patients, their use is limited by severe 
adverse effects, as for high doses of prednisone, or by a narrow pharmacological window, as 
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in the case of ibuprofen (Birke, 2001; Koehler, 2004; Konstan, 2005). The endobronchial location 
makes CF pulmonary inflammation potentially amenable to inhaled therapies, thus achieving 
much higher concentrations in the airway epithelium and limiting the adverse effects of long 
term systemic use. As the airway epithelium is targeted by inhaled agents, bronchial epithelial 
cells in vitro have been widely used to prove the efficacy of these drugs. The glucocorticoid 
dexamethasone, largely used in the treatments of inflammatory conditions is scarcely effective 
in reducing the expression of the chemokine IL-8 in CF bronchial epithelial cells (Figure 1). As 
a matter of fact, it produces inhibitory effect only at the higher dose (30 M) (Figure1A) in CF 
bronchial epithelial IB3-1 cells whereas it fails to reduce the transcription of IL-8 in Cufi-1 cells 
(Figure 1B). Different from the results obtained in CF CuFi-1 cells, treatment with 
dexamethasone results in reducing the inflammatory response, in non CF NuLi-1 cells (Figure 
1C). These findings suggest that CF bronchial cells seem to be resistant to GC treatment, 
consistent with scarce efficacy of GC treatment observed in CF patients. 
3. P.aeruginosa stimulated IL-8 mRNA expression is reduced in CF bronchial 
epithelial cells treated with inhibitors of SL metabolism miglustat and NB-
DGJ 
The role of CFTR deficiency in promoting inflammation remains unclear. Inhibition of 
function of wild type CFTR by CFTRinh172 (Perez, 2007) or correction of F508del mutated 
CFTR function by MPB-07 or miglustat (Dechecchi, 2007; 2008) regulates the inflammatory 
response to P. aeruginosa, suggesting that the pro-inflammatory circuitry in CF airways 
could be initiated from those epithelial cells lacking CFTR function. However the galactose 
analogue N-butyldeoxygalactonojirimycin (NB-DGJ), which is not a corrector of F508del-
CFTR function (Norez, 2006), similarly reduces the PAO1 stimulated IL-8 mRNA expression 
in CF cells (Figure 2). Additionally this reduction has been obtained both in CF and non CF 
cells with both miglustat and NB-DGJ (Dechecchi, 2008). Therefore, miglustat affects the 
inflammatory response to P. aeruginosa through a mechanism which, at least partly, is 
independent of the correction of F508del-CFTR function. As far as the effect of miglustat and 
NB-DGJ on immune response is concerned, they could affect the host response to 
P.aeruginosa through the regulation of SL metabolism, in particular CerGlcT and/or non 
lysosomal glucosylceramidase, an activity shared by both compounds (Butters, 2005), thus 
strengthening the notion that the metabolism of SLs can be manipulated as a therapeutic 
option for CF lung disease.  
4. Amitriptyline reduces IL-8 gene expression in CF bronchial cells 
Two main routes have been defined for the generation of ceramide: hydrolysis of 
sphingomyelin (SM) by acid sphingomyelinase (ASM) and de novo biosynthesis (Hannun, 
2008). Ceramide generated by ASM plays an important role in the infection by P. aeruginosa 
since it reorganizes into rafts required to internalize bacteria, induce apoptosis and regulate 
the cytokine response (Grassme’, 2003). Treatment of CF mice by ASM inhibitors, such as 
amitriptyline and others tricyclic antidepressants, has been shown to reduce the degree of 
inflammation (Teichgraber, 2008; Becker, 2010). Notably, amitriptyline results in dose 
dependent inhibition of IL-8 transcription by bronchial epithelial cell lines IB3-1 and CuFi-1, 
infected with P.aeruginosa (Figure 3), consistent with the overall anti-inflammatory  
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Fig. 1. Effect of dexamethasone on inflammatory response to P.aeruginosa in CF and non CF 
bronchial epithelial cells. 
IB3-1 (human bronchial epithelial cell line) (Zeitlin, 1991) (A), CuFi-1 (F508del/F508del 
CFTR mutant genotype) (B) and NuLi-1 (C), (wild type CFTR) (Zabner, 2003) cell lines were 
treated with dexamethasone, at doses indicated in the figure, or solvent alone, for 24 hours 
and then infected with P.aeruginosa strain PAO1 (kindly provided by A. Prince, Columbia 
University, New York)(50CFU/cell) for 4 hours at 37° C. The inflammatory response was 
evaluated by studying the expression of mRNA of IL-8, measured by Real-time qPCR as 
described (Dechecchi, 2008) and obtained by comparing the ratio IL-8 and the housekeeping 
gene GAPDH between non infected and infected cells. Results are expressed as mean  
standard error of the mean (n=5). Comparisons between groups were made by using 
Student’s t test. Statistical significance was defined with p0.05. * , p value <0.05. 
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(a) (b) 
Fig. 2. Result of miglustat and NB-DGJ on P.aeruginosa stimulated IL-8 mRNA expression in 
CF bronchial cell lines IB3-1 and CuFi-1 cells. 
IB3-1 (A) and CuFi-1 (B) cells were treated with miglustat, NB-DGJ, at doses indicated in the 
figure, or solvent alone for 24 hours and then infected with PAO1 as in Figure 1. Stimulated 
IL-8 mRNA expression was calculated as indicated in the legend of Figure 1 and expressed 
as % of untreated cells. Data reported are mean  standard error of the mean of 3 
independent experiments, performed in duplicate. **, p value < 0.01; ***, p value < 0.001. 
 
(a) (b) 
Fig. 3. Result of amitriptyline on P.aeruginosa stimulated IL-8 mRNA expression in CF 
bronchial cell lines IB3-1 and CuFi-1 cells 
IB3-1 (A) and CuFi-1 (B) cells were treated with amitriptyline, at doses indicated in the figure, 
or solvent alone for 24 hours and then infected with PAO1 as in Figure 1. Stimulated IL-8 
mRNA expression was calculated as indicated in the legend of Figure 1 and expressed as % of 
untreated cells. Data reported are mean  standard error of the mean of 8 (IB3-1) or 6 (CuFi-1) 
independent experiments, performed in duplicate. *, p value <0.05; **, p value < 0.01. 
www.intechopen.com
 
Cystic Fibrosis – Renewed Hopes Through Research  
 
444 
effect reported in CF murine lungs (Teichgraber, 2008; Becker, 2010). Interestingly, we have 
recently demonstrated that, besides inhibiting IL-8 transcription, both miglustat and 
amitriptyline reduce the P.aeruginosa induced immunoreactive ceramide expression 
(Dechecchi, 2011), by targeting different pathways of SL metabolism: CerGlcT and/or non-
lysosomal glucosylceramidase (miglustat) and ASM (amitriptyline). As far as the effect on 
immune response is concerned, the same overall decrease of ceramide could regulate the 
transmembrane signaling between the receptors for pathogens and the transcription of the 
inflammatory genes, thus reducing inflammation.  
5. Miglustat and amitriptyline inhibit the pro-inflammatory signaling 
downstream the receptors for P.aeruginosa and for pro-inflammatory 
cytokines 
The importance of ceramide as a pro-inflammatory mediator derives from its capability to 
activate protein kinases and phosphatases in different downstream pathways and from the 
generation of second messengers (Hannun, 2008). Ceramide is produced in response to 
various stimulants such as cytokines, heat, UV radiation, lipopolysaccharide (LPS) and other 
agents thus leading to specific and overlapping events that include the activation of a common 
set of kinases and transcription factors. Both miglustat and amitriptyline inhibit the expression 
of IL-8 mRNA stimulated by either P.aeruginosa or TNF or IL-1 (Figure 4), indicating that 
they affect the pro-inflammatory signaling downstream and in common with the receptors for 
P. aeruginosa and for these pro-inflammatory cytokines. Importantly, ceramide-induced 
activation of the transcription factor NF-kB and p38 kinase amplifies the production of several 
inflammatory mediators and adhesion molecules (Won, 2004). Therefore, it can be 
hypothesized that miglustat and amitriptyline, decreasing plasma membrane ceramide, 
generated by P.aeruginosa infection or pro-inflammatory cytokines, attenuate the activation of 
NF-kB mediated signaling cascade which in turn down-regulates the immune response. 
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Fig. 4. Effect of miglustat and amitriptyline on IL-8 gene expression stimulated by 
P.aeruginosa, TNF or IL-1.  
IB3-1 cells were treated with miglustat (100M), amitriptyline (10M) or solvent alone for 24 
hours and then infected with PAO1 or stimulated by the pro-inflammatory cytokines TNF  
(10ng/ml) or IL-1  (50 ng/ml) for 4 hours at 37°C as in Figure 1. Stimulated IL-8 mRNA 
expression was calculated as indicated in the legend of Figure 1 and expressed as % of 
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untreated cells. Data reported are mean  standard error of the mean of 3 independent 
experiments performed in duplicate. *, p value <0.05; **, p value < 0.01; ***, p value < 0.001.  
6. Miglustat down-regulates the expression of key genes involved in 
neutrophil chemotaxis in human bronchial CF epithelial cells 
The infection of a host by a pathogenic microorganism initiates complex cascade of events 
directed toward the recruitment of defence mechanisms. Parallel analysis of gene expression 
provides a new tool for studying interplay of signals and transcriptional responses in biological 
systems. Infection of IB3-1 cells with the P.aeruginosa strain PAO1, for a short time (4 hours), up-
regulates the expression of genes involved in the inflammatory response, mainly neutrophil 
chemotaxis, such as the chemokines IL-8, Gro-, GCP-2, the adhesion molecule ICAM-1, the 
cytokines IL-1 IL-6, TNF-, the antimicrobial peptide HBD-4, Toll-like receptor 2 and 
NFKB1 (Figure 5A). These results obtained in CF cell line correlate with findings in cultured 
human bronchial epithelial primary cells derived from the bronchi of CF patients (Figure 5B), 
which exhibit many of the morphological and functional characteristics believed to be 
associated with CF airway disease (Neuberger, 2011) and recall many features of the 
colonization of the respiratory epithelium by pathogens. As far as host defence mechanisms are 
concerned, bronchial epithelium is not simply a physical barrier against invading pathogens but 
is also an important source of inflammatory mediators, actively involved in the immune 
response. Therefore cultured CF bronchial cells provide a useful tool for the pre-clinical testing 
of novel pharmacotherapies. Indeed, miglustat has an anti-inflammatory effect in CF bronchial 
cells, since it reduces the expression of key genes induced by P.aeruginosa and IL-8 protein 
release (Dechecchi, 2011). Also amitriptyline has an anti-inflammatory effect in CF bronchial cell 
lines (Figure 5A) and at lower extent in CF primary cells (Figure 5B). Regarding the therapeutic 
activity of amitriptyline, it should be noted that systemic inhibition of ASM might negatively 
affect the host defence, as demonstrated by studies on mice completely lacking ASM which 
were found to be unable to control infections (Grassme’, 2003). Moreover, since amitriptyline 
inhibits serotonin and noradrenaline uptake in presynaptic nerve ending (Maubach, 1999), it 
might cause severe adverse effects in long term use in CF children. As with all treatments, 
utility will largely depend on the balance between potential risks and benefits. 
7. Miglustat up-regulates the transcription of the antimicrobial peptide HBD-4  
The treatment of CF patients with drug aimed to limit the excessive inflammatory response 
could mean that they become vulnerable to infections. As a matter of fact, dexamethasone 
down-regulates the expression of HBD-4 (Figure 6), an antimicrobial peptide induced by 
infectious or inflammatory stimuli, that plays an important role in the host innate immune 
response, with strong activity against P.aeruginosa (Yanagi, 2005). This result is consistent 
with suppression of b-defensins by GC treatment, already reported (Jang, 2007). On the 
other hand, well known huge side effects of long term use of steroids limit their clinical 
utility in CF patients (Nichols, 2008). On the contrary, miglustat up-regulates the expression 
of HBD-4, both in cell lines and primary cells (Figures 5 and 6), adding ground to the 
suggestion that miglustat could not compromise the ability to resist infection with 
pathogens in CF patients. Additionally, results on the safety of miglustat obtained during 
the first 5 years of the clinical studies, do not report any increased susceptibility to bacterial 
infections in patients affected by Gaucher disease (Hollak, 2009). All this considered the 
proximity to a treatment of CF lung inflammation with miglustat is real and promising. 
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Fig. 5. Inflammatory response to P.aeruginosa in IB3-1 and CF primary cells treated with 
miglustat or amitriptyline. 
IB3-1 cells (A) and human airway epithelium reconstituted in vitro with cells isolated from 
CF patients and cultivated on micro-porous filters at air-liquid interface (MucilAir™, 
Epithelix Sàrl, Genève, Switzerland) (B) were treated with miglustat (100M), amitriptyline 
(10M) or solvent alone for 24 hours and then infected with PAO1. The inflammatory 
response was evaluated by studying the expression of several genes known to be associated 
with host immune defences by RNA macroarrays (TaqMan Low Density Array, Applied 
Biosystems, Foster City, CA) as detailed (Dechecchi, 2011). Stimulated mRNA expression 
was calculated as indicated in the legend of Figure 1 and expressed as % of untreated cells. 
(A) IB3-1 cells. Miglustat significantly reduces the expression of IL-8, ICAM-1, TNF- (**, p 
value<0.01), gro-, GCP-2, IL-1IL-6 and NFKB1(*, p value<0.05) and increases the 
expression of HBD-4 (**, p value<0.01). Amitriptyline significantly reduces the expression of 
IL-8, Gro-, ICAM-1 (**, p value<0.01), gro-, GCP-2, IL-1IL-6, TNF- and NFKB1(*, p 
value<0.05) (n=6). (B) CF primary cells. Miglustat significantly reduces the expression of IL-
8, GCP-2, ICAM-1, TNF-, IL-6 (*, p value<0.05) and increases the expression of HBD-4 (*, p 
value<0.05). Amitriptyline significantly reduces the expression of GCP-2, ICAM-1, IL-IL-
6 (*, p value<0.05) and increases the expression of HBD-4 (*, p value<0.05) (n=4).  
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Fig. 6. P.aeruginosa stimulated transcription of the antimicrobial peptide HBD-4 in IB3-1 
cells: result of miglustat and dexamethasone.  
IB3-1 cells were treated with miglustat (100M), dexamethasone (30M) or solvent alone for 
24 hours and then infected with PAO1 as in Figure 1. Stimulated HBD-4 mRNA expression 
was measured by Real-time qPCR as described (Dechecchi, 2011), calculated as indicated in 
the legend of Figure 1 and expressed as % of untreated cells. Data reported are mean  
standard error of the mean of 5 independent experiments performed in duplicate. **, p 
value<0.01 (miglustat); *, p value<0.05 (dexamethasone). 
8. Miglustat down-regulates neutrophil chemotaxis in the early inflammatory 
response in vivo 
The pressing challenge for the discovery of new drugs is to transform findings from bench 
studies into effective therapies. The success of results obtained with CFTR correctors and 
potentiators suggests that primary coltures of human airway epithelia will likely be the 
model system of choice for future proof of principle studies of experimental therapeutics 
(Neuberger, 2011). With regard to miglustat, the anti-inflammatory effect observed in CF 
primary cells (Dechecchi, 2011) provides a significant body of evidence concerning the 
utility of miglustat in modifying lung inflammation. However, an essential requirement for 
entering clinical trial is a thorough testing in pre-clinical animal models. As a matter of fact 
development of new animal models of CF such as CFTR knock-out pigs (Rogers, 2008), 
raises the possibility to employ these animals to evaluate new treatments. Murine models of 
acute and chronic infection with P.aeruginosa, along with mice genetically modified for the 
CFTR gene, are a key asset in CF research and mimic many of the characteristic features of 
CF lung pathology (Bragonzi, 2010). Additionally, mice with the airway specific over 
expression of the Na+ channel ENaC, develop a CF−like lung inflammation (Mall, 2004). 
These models have provided insights in the effectiveness of anti-inflammatory therapy in 
reducing lung damage. Interestingly, lung inflammation of ENaC over expressing mice 
seems to be resistant to GC treatment (Livraghi, 2009) and amitriptyline reduces the degree 
of inflammation in CFTR-/- mice (Teichgraber, 2008; Becker 2010). As far as the 
effectiveness of miglustat is concerned, it reduces the recruitment of PMN into the 
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bronchoalveolar space induced by intranasal instillation of LPS (Figure 7A) (Dechecchi, 
2011). The pharmacokinetic profile and tissue distribution of miglustat, after oral dosing in 
small rodents, demonstrate that it is well absorbed, exhibits a bioavailability of 40-60%, is 
widely distributed within the body and, notably, it is present at high concentrations in the 
lung 1 hour after administration (Treiber, 2007). Indeed, a treatment schedule of an oral 
administration with miglustat one hour before the intra tracheal inoculum with P. aeruginosa 
is effective in reducing the inflammatory response associated to acute pneumonia in terms 
of leukocyte recruitment and myeloperoxidase (MPO) activity in the airways (Figure 7B and 
Figure 7C). Taken together, these results indicate that miglustat may down-regulates 
neutrophil recruitment in the early phase of the inflammatory response.  
  
(a) (b) 
 
 
c 
Fig. 7. Effect of miglustat on murine models of lung inflammation.  
(A). Aqueous solution of miglustat (100 mg/Kg) or vehicle alone was administered once daily 
in wild type C57BL/6J mice by intraesophageal gavage, for a period of three consecutive days 
before pro-inflammatory challenge with LPS by intranasal instillation. Bronchoalveolar lavage 
fluid (BALF) was examined 4 hrs after challenge, as described (Dechecchi, 2011). Data reported 
are mean  standard error of the mean. n=6(vehicle), n=12 (miglustat). ***, p value < 0.001. (B 
and C). C57BL/6 mice were infected by intra-tracheal injection with the reference P. aeruginosa 
strain PAO1 (1x105 CFU) one hour after oral injection with miglustat (400mg/kg), or vehicle. 
Mice were sacrificed 4 hours after PAO1 injection and the inflammatory response associated to 
PAO1-induced acute pneumonia in terms of leukocyte recruitment (B) and MPO activity (C) in 
the airways was analyzed as described (Bragonzi, 2009, Moalli, 2011). Data reported are mean 
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 standard error of the mean. n=5 (vehicle), n=6 (miglustat). ***, p value < 0.001(leukocyte 
recruitment); **, p value < 0.01(MPO activity). 
9. Conclusions 
Strategies aimed to limit the excessive inflammatory response by targeting neutrophil 
recruitment are a relevant approach for CF patients. In general, each anti-inflammatory 
molecule should balance between the anti-infective role of neutrophils and the detrimental 
effects that they produce in the course of chronic inflammation due to the release of 
proteases and reactive oxygen species. In this respect, while others anti-inflammatory based 
therapies have failed in humans with CF in the past, the regulation of SLs may represent a 
useful potential target for pharmacotherapy. This review summarizes evidence derived 
from the validation of the anti-inflammatory properties of miglustat in bronchial epithelial 
cells in vitro and in murine models of lung inflammation and infection in vivo, 
demonstrating a down-regulation of neutrophils chemotactic signaling. Recalling that 
miglustat is an orally bioavailable FDA-approved and EMA−designated orphan available 
drug, therapeutic trials for CF patients could be envisioned in the near future. 
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